pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 8·1 min read
save

Top young AI researchers avoid careers at large pharmaceutical companies

May 8, 2026·read at Endpoints ↗Negative

Mazdak Abulnaga, a 33‑year‑old postdoctoral fellow at MIT and Harvard Medical School, is highlighted as the type of employee pharmaceutical companies hope to attract this year.

Despite the demand, many leading AI professionals are showing little interest in joining big drugmakers, opting instead for roles in academia, startups, or other technology sectors.

The trend signals a hiring challenge for the pharma industry, prompting companies to rethink how they attract and retain top AI talent.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “'Pharma, not really’: Top young AI talent shuns careers at big drugmakers”

read at Endpoints ↗
102 words · retrieved May 8
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING

related stories

  • May 4Opinion: Are blue zones real? Answering that question is harder than everSTAT
  • May 2Federal appeals court blocks mailing of abortion pill mifepristoneSTAT
  • May 1Arvinas’ ‘Protac’ breast cancer drug cleared by FDABioPharma Dive
  • Apr 30Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstoodSTAT
  • Apr 30Merck still sees ‘compelling’ outlook for Terns leukemia drugBioPharma Dive